MaxCyte (MXCT) is maintaining excellent commercial momentum across its cell therapy business, which led to 21% year-on-year top-line growth to US$26.2mln in fiscal (FY) 2020. This included three new strategic licences with high profile cell therapy developers, a fourth signed post period, a rise in
29 Apr 2021
MaxCyte: 2020 revenues up 21% as industry enters new growth era
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
MaxCyte: 2020 revenues up 21% as industry enters new growth era
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
29 Apr 2021 -
Author:
Emma Ulker -
Pages:
4
MaxCyte (MXCT) is maintaining excellent commercial momentum across its cell therapy business, which led to 21% year-on-year top-line growth to US$26.2mln in fiscal (FY) 2020. This included three new strategic licences with high profile cell therapy developers, a fourth signed post period, a rise in